Can-Fite Receives FDA Feedback With Respect To Development And Registration Plans For Piclidenoson; FDA Encouraged Co. To Enroll Adolescent Patients Due To The Strong Safety Profile Of The Drug Demonstrated Over The Development History And Prior Studies
Portfolio Pulse from Benzinga Newsdesk
Can-Fite has received positive feedback from the FDA regarding the development and registration plans for Piclidenoson. The FDA has encouraged the company to enroll adolescent patients due to the strong safety profile of the drug demonstrated over its development history and prior studies.
June 29, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Can-Fite's stock may see positive movement due to the FDA's encouraging feedback on the development and registration plans for Piclidenoson.
The FDA's positive feedback and encouragement to enroll adolescent patients due to the strong safety profile of Piclidenoson is a significant development for Can-Fite. This could potentially expand the drug's market and increase investor confidence, leading to a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100